Novo’s EVOKE Ph3 Alzheimer’s trial update: oral sema potential neuro pivot
Key Questions
What was the outcome of Novo Nordisk's EVOKE Phase 3 trial?
EVOKE Ph3 completed April 7, 2026, with data confirming a flop. It raises questions on growth beyond obesity/diabetes. Stock rose +1.5% to $37.52 despite this.
How did the market react to the EVOKE trial update?
Shares gained 1.5% to $37.52 amid the flop confirmation. Investors question pipeline diversification. Oral semaglutide eyed for neuro pivot potential.
What does the EVOKE update mean for Novo Nordisk's future growth?
It highlights challenges expanding beyond obesity care. Trial failure underscores reliance on core areas. Update fuels debates on long-term strategy.
Ph3 complete Apr7 2026; data flop confirmed, stock +1.5% to $37.52 amid growth beyond obesity questions.
Sources (2)
Updated Apr 12, 2026